TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8872694
Drug: Intramuscular glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular glycopyrrolate
Study: 31143882
Drug: CC‐Cruiser
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC‐Cruiser
Study: 30241687
Drug: Pregabalin 300
Normalized name: pregabalin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300 mg BID for 6 times
Study: 30241687
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioctic acid 600 mg once daily for 3 times
Study: 30241687
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pregabalin and thioctic acid
Study: 24708735
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 50,000 IU vitamin A
Study: 20081227
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (cilostazol, thienopyridine, aspirin)
Study: 20081227
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (thienopyridine, aspirin)
Study: 20081227
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy and Dual therapy
Study: 12052603
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol moistened with 1 mL of 3% acetic acid solution
Study: 12052603
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol in dry tablet form
Study: 10397281
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg) in OC+ subjects
Study: 10397281
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg) in OC- subjects
Study: 10397281
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg) in both OC+ and OC- subjects
Study: 10397281
Drug: Alcohol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.5 g/kg) in OC+ subjects during midcycle
Study: 10397281
Drug: Alcohol (0.34-1.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.34-1.02 g/kg) in OC+ subjects (substudy)
Study: 29627620
Drug: LUB 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUB 12 μg
Study: 29627620
Drug: LUB 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUB 24 μg
Study: 25252727
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cefetamet sodium for IV infusion over 30 minutes
Study: 25252727
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of cefetamet sodium for IV infusion over 30 minutes
Study: 25252727
Drug: 2000 mg
Normalized name: bran 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 mg of cefetamet sodium for IV infusion over 30 minutes
Study: 23949430
Drug: Dinaciclib 50
Normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinaciclib 50 mg/m² given as a 2-h infusion every 21 days
Study: 15858936
Drug: Nitroglycerin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (3 microg/kg) added to the cardioplegic solution
Study: 15858936
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 microg/kg) added to the cardioplegic solution
Study: 14503094
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid for 10 days
Study: 10374221
Drug: Estrogen-androgen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-androgen therapy (0.625 mg esterified estrogens combined with 1.25 mg methyltestosterone)
Study: 10374221
Drug: Estrogen-androgen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-androgen therapy (1.25 mg esterified estrogens combined with 2.5 mg methyltestosterone)
Study: 10374221
Drug: Estrogen-only therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-only therapy (0.625 mg esterified estrogens)
Study: 10374221
Drug: Estrogen-only therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-only therapy (1.25 mg esterified estrogens)
Study: 10374221
Drug: Estrogen-androgen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-androgen therapy
Study: 10374221
Drug: Estrogen-androgen treatment
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-androgen treatment
Study: 6345023
Drug: Drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug therapy (group 2)
Study: 18325516
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of E(2) from days 3 to 5 (group 1)
Study: 18325516
Drug: No hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormonal treatment (group 2)
Study: 18325516
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of E(2) for 15 days (group 3)
Study: 17190528
Drug: Stimulant and
Normalized name: norgestimate and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant and nonstimulant medications
Study: 17190528
Drug: Long-acting medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting medications
Study: 17190528
Drug: Negotiated trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negotiated trial of time off treatment
Study: 9752283
Drug: Granisetron (Gra)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (Gra) 1 mg
Study: 9752283
Drug: Ondansetron (Ond)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (Ond) 8 mg
Study: 748488
Drug: Fluocinolone cream
Normalized name: fluocinolone Topical Cream
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinolone cream applied twice a day for five days
Study: 748488
Drug: Inert carrier
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert carrier base applied twice a day for five days
Study: 20716911
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of creatine (Cr)
Study: 15231367
Drug: Methylprednisolone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (16 mg for 4 weeks tapered to 4 mg for 4 months)
Study: 10646895
Drug: L-carnitine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine treatment in tumour-bearing mice
Study: 8958001
Drug: Ethanol (0.66
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (0.66 g ethanol/kg orally followed by 0.1 g ethanol/kg per h intravenously)
Study: 8958001
Drug: Control (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (identical volumes of oral water and intravenous saline)
Study: 9860036
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate 200 microg once daily
Study: 8589159
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/[kg.d]; maximum 400 mg) once a day for 4 days
Study: 8589159
Drug: Rifampin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (20 mg/kg; maximum, 600 mg) once a day for 4 days
Study: 2283715
Drug: Cefdinir granules
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir granules at a dose of 3 mg/kg
Study: 2283715
Drug: Cefdinir granules
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir granules at a dose of 6 mg/kg
Study: 2283715
Drug: Cefdinir granules
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir granules at daily doses of 9.0‐20.7 mg/kg in 3 divided portions
Study: 31510721
Drug: Bilateral PC6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral PC6 sham injection of 0.9% sodium chloride + intravenous granisetron (Group A, n=31)
Study: 31510721
Drug: Bilateral acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral acupuncture point injection at PC6 of 0.9% sodium chloride + intravenous 0.9% sodium chloride (Group B, n=33)
Study: 31510721
Drug: Bilateral acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral acupuncture point injection at PC6 of 0.9% sodium chloride + intravenous granisetron (Group C, n=30)
Study: 25890480
Drug: Cellular immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular immunotherapy (CIT) with autologous natural killer cells, γδT cells, and cytokine‐induced killer cells in combination with chemotherapy
Study: 25890480
Drug: Cellular immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellular immunotherapy (CIT) with chemotherapy
Study: 23487517
Drug: Betrixaban 40
Normalized name: betrixaban 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban 40 mg once daily
Study: 23487517
Drug: Betrixaban 60
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betrixaban 60 mg once daily
Study: 23487517
Drug: Betrixaban 80
Normalized name: betrixaban 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betrixaban 80 mg once daily
Study: 23487517
Drug: Warfarin (adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted to INR 2.0-3.0)
Study: 8191242
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil 100 mg bid for 5 days (n = 113)
Study: 8191242
Drug: Phenoxymethyl penicillin
Normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethyl penicillin 600 mg tid for 10 days (n = 107)
Study: 12855349
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream and oral glucose (1 ml of glucose at 300 mg/ml)
Study: 12855349
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream and oral glucose
Study: 12855349
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and water
Study: 10100592
Drug: Granisetron injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron injection (40 microg/kg) via 30-min infusion
Study: 10100592
Drug: Granisetron injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron injection (40 microg/kg) via slow intravenous injection over 30 s
Study: 10100592
Drug: Granisetron injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron injection (40 microg/kg) via 30-min infusion and slow intravenous injection
Study: 8739815
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen administered (normoxaemia)
Study: 26252749
Drug: Amoxicillin 2
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 2 g
Study: 23718900
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg vinorelbine, taken orally three times a week
Study: 23718900
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg vinorelbine, taken orally three times a week
Study: 23718900
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg vinorelbine, taken orally three times a week
Study: 23718900
Drug: Low pre-treatment
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low pre-treatment blood concentrations of FGF2 and IL8
Study: 19411056
Drug: Nutrition education
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition education and gardening (NE+G)
Study: 17539707
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using a laser source with a wavelength of 690 nm associated with a phenothiazine photosensitizer
Study: 7917929
Drug: Tamoxifen and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen and prednisolone, 7.5 mg daily
Study: 28263288
Drug: Adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted influenza vaccine (MF59)
Study: 26814087
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose group (Group A)
Study: 8822656
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin (2.5 mU/minute initial dose, increments of 2.5 mU/minute)
Study: 8822656
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (1.25 mU/minute initial dose, increments of 1.25 mU/minute)
Study: 4061901
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg lidocaine intravenously
Study: 4061901
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg lidocaine intravenously
Study: 4061901
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg lidocaine intravenously
Study: 4061901
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg lidocaine intravenously
Study: 4061901
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg lidocaine intravenously
Study: 25612603
Drug: RATG (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RATG (0.5 mg/kg/day)
Study: 25612603
Drug: RATG plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RATG plus basiliximab (20 mg on days 0 and 4)
Study: 25612603
Drug: AZA therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZA therapy
Study: 25612603
Drug: MMF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMF therapy
Study: 17524873
Drug: Oral valgancyclovir
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valgancyclovir for 2 weeks (VAL2w)
Study: 17524873
Drug: Oral valgancyclovir
Normalized name: valganciclovir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral valgancyclovir for 3 months (VAL3m)
Study: 17524873
Drug: Intravenous gancyclovir
Normalized name: Gancyclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous gancyclovir for 2 weeks (GAN)
Study: 9526931
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral diazepam
Study: 11271312
Drug: Higher oral
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher oral FK 506 dose (0.19 mg/kg bw per day) in early phase of multicenter trial
Study: 11271312
Drug: Lower oral
Normalized name: melatonin/val/chamomile flower ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower oral FK 506 dose (0.14 mg/kg bw per day) in late phase of multicenter trial
Study: 11271312
Drug: Further reduced
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Further reduced FK 506 dosage (0.10 mg/kg bw per day or less) in recent single centre treatment
Study: 2459543
Drug: Felodipine 1
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 1 mg intravenous infusion
Study: 2459543
Drug: Felodipine 3
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 3 mg intravenous infusion
Study: 2459543
Drug: Felodipine 5
Normalized name: felodipine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 5 mg oral solution
Study: 2459543
Drug: Felodipine 15
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 15 mg oral solution
Study: 2459543
Drug: Felodipine 40
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 40 mg oral solution
Study: 15784645
Drug: Conventional Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Control (CC)
Study: 30942007
Drug: Oral mecobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mecobalamin dispersible tablets and multivitamin B tablets within 3 days after onset, acupuncture started from the 4th day (Group B)
Study: 30942007
Drug: Oral mecobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mecobalamin dispersable tablets and multivitamin B tablets within 5 days after onset, acupuncture from the 6th day (Group C)
Study: 30942007
Drug: Oral mecobalamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mecobalamin dispersable tablets and multivitamin B tablets within 7 days after onset, acupuncture from the 8th day (Group D)
Study: 21663717
Drug: Preoperative interscalene
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative interscalene block with 30 mL of 0.5% ropivacaine
Study: 21663717
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 10 mL of saline solution
Study: 9241285
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2000 mg/day)
Study: 3549507
Drug: Sclerotherapy (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (1% polidocanol, performed twice weekly until varices eradicated)
Study: 3549507
Drug: Propranolol (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (twice daily, mean dose 161 +/- 80 mg per day)
Study: 26763851
Drug: Losartan potassium
Normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan potassium tablets (50‐100 mg per day)
Study: 26763851
Drug: Levamlodipine besylate
Normalized name: Levamlodipine besylate
DrugBank: Levamlodipine (DB09237)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levamlodipine besylate tablets (2.5‐5.0 mg per day)
Study: 25068412
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block (FICB) using 40 mL ropivacaine 0.5%
Study: 25068412
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (IVFE) 1.5 μg/kg
Study: 22709704
Drug: Baked beetroot
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked beetroot (200 g with ≥500 mg nitrate)
Study: 18626166
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg and Normal saline (Group C)
Study: 15728536
Drug: Animal compound-free
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal compound-free (ACF) medium
Study: 12574563
Drug: Dexamphetamine (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (2.5, 5, or 10 mg orally twice daily)
Study: 7028085
Drug: Simultaneous timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simultaneous timolol and epinephrine treatment
Study: 31674920
Drug: Daily emotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily emotion ratings (control group)
Study: 26154926
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate citrate (FPC) administered via dialysate (2 μmol/l of iron)
Study: 26154926
Drug: Ferric pyrophosphate
Normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric pyrophosphate citrate (FPC) administered via dialysate
Study: 21084403
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin treatment (IIT) for 24 hours targeting glycemia less than 110 mg/dl
Study: 21084403
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) with regular insulin if glycemia was greater than 200 mg/dl
Study: 17289894
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m2 (weekly)
Study: 17289894
Drug: Cetuximab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (single doses of 250-500 mg/m2)
Study: 17289894
Drug: Cetuximab (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (various single doses: 50, 100, 250, 400, 500 mg/m2)
Study: 17289894
Drug: Cetuximab (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (250 mg/m2)
Study: 15498524
Drug: Dimethylglycine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimethylglycine (400 mg daily for 28 days)
Study: 15498524
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily for 28 days)
Study: 14563654
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day orally)
Study: 30054895
Drug: Ceftazidime 2000-500
Normalized name: ceftazidime 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 2000-500 mg every 8 hours
Study: 30054895
Drug: Avibactam 2000-500
Normalized name: avibactam 500 MG / ceftazidime 2000 MG [Avycaz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avibactam 2000-500 mg every 8 hours
Study: 26757276
Drug: Three-dose intramuscular
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose intramuscular (i.m.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Study: 26757276
Drug: Three-dose intravenous
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose intravenous (i.v.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Study: 26757276
Drug: Five-dose intramuscular
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-dose intramuscular (i.m.) artesunate regimen (2.4 mg/kg at 0, 12, 24, 48, and 72 hours)
Study: 24216034
Drug: darunavir/ritonavir 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: darunavir/ritonavir 800/100 mg once daily monotherapy